BofA/Merrill Lynch Upgrades Perrigo Co. (PRGO) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Perrigo (PRGO) Tops Q3 EPS by 7c; Will Explore Strategic Alternatives for Tysabri
November 10, 2016 6:23 AM ESTPerrigo (NYSE: PRGO) reported Q3 EPS of $1.65, $0.07 better than the analyst estimate of $1.58. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.28 billion.
Perrigo also announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug Tysabri® (natalizumab).
Perrigo's CEO... More
